The long-term persistence of islet cell antibodies in Type I diabetic patients is unrelated to residual β-cell function

E. Bosi, A. C. Andreotti, A. M. Girardi, G. F. Bottazzo, G. Pozza

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Islet cell antibodies (ICA) disappear in most Type I diabetic subjects within months or a few years after diagnosis, possibly reflecting the disappearance of β-cell autoantigen. In a minority of patients, ICA tend to persist indefinitely. The aim of this study was to evaluate whether the persistence of ICA reflects the persistence of functioning β-cell as a source of autoantigen immunization. In 19 longstanding Type I diabetic patients, selected for having (n = 9) detectable ICA (64.4 ± 8.01 JDF units) or not (n = 10) and matched for the duration of the disease (17.1 ± 3.6 vs 19.1 ± 1.5 yr, respectively), C-peptide secretion was evaluated by an i.v. glucagon test. The insulin requirement and metabolic control of patients with ICA were similar to those without detectable ICA. In contrast, patients with ICA were mostly females (p <0.02), older at diagnosis (p <0.02), with a higher prevalence of associated thyroid (p <0.005) and gastric (p <0.05) autoantibodies and autoimmune diseases (p <0.02). No differences were observed between patients with or without ICA in basal (0.2 ± 0.06 vs 0.10 ± 0.58 pg/ml at 0 min, NS) and glucagon-stimulated (0.23 ± 0.07 vs 0.31 ± 0.16 pg/ml at 6 min, NS) C-peptide levels, showing a virtually absent β-cell secretion in the two groups. These findings indicate that: 1) ICA in some Type I diabetic subjects may persist in the absence of a residual C-peptide secretion and therefore independently of the fate of β-cell autoantigen(s); 2) the long-term persistence of ICA identifies Type I diabetic patients as preferentially female, with an older age of onset and with other associated organ-specific autoimmunities; 3) the mechanisms of islet autoimmune response are heterogeneous.

Original languageEnglish
Pages (from-to)319-323
Number of pages5
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Volume4
Issue number4
Publication statusPublished - 1991

Fingerprint

islets of Langerhans
antibodies
autoantigens
cells
C-Peptide
Autoantigens
autoimmunity
glucagon
secretion
peptides
Glucagon
Autoimmunity
islet cell antibody
Stomach Diseases
autoantibodies
autoimmune diseases
Age of Onset
Autoantibodies
Autoimmune Diseases
Immunization

ASJC Scopus subject areas

  • Food Science
  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The long-term persistence of islet cell antibodies in Type I diabetic patients is unrelated to residual β-cell function. / Bosi, E.; Andreotti, A. C.; Girardi, A. M.; Bottazzo, G. F.; Pozza, G.

In: Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 4, No. 4, 1991, p. 319-323.

Research output: Contribution to journalArticle

@article{4e0fd7db7f8d424dbeca0f97b79291b8,
title = "The long-term persistence of islet cell antibodies in Type I diabetic patients is unrelated to residual β-cell function",
abstract = "Islet cell antibodies (ICA) disappear in most Type I diabetic subjects within months or a few years after diagnosis, possibly reflecting the disappearance of β-cell autoantigen. In a minority of patients, ICA tend to persist indefinitely. The aim of this study was to evaluate whether the persistence of ICA reflects the persistence of functioning β-cell as a source of autoantigen immunization. In 19 longstanding Type I diabetic patients, selected for having (n = 9) detectable ICA (64.4 ± 8.01 JDF units) or not (n = 10) and matched for the duration of the disease (17.1 ± 3.6 vs 19.1 ± 1.5 yr, respectively), C-peptide secretion was evaluated by an i.v. glucagon test. The insulin requirement and metabolic control of patients with ICA were similar to those without detectable ICA. In contrast, patients with ICA were mostly females (p <0.02), older at diagnosis (p <0.02), with a higher prevalence of associated thyroid (p <0.005) and gastric (p <0.05) autoantibodies and autoimmune diseases (p <0.02). No differences were observed between patients with or without ICA in basal (0.2 ± 0.06 vs 0.10 ± 0.58 pg/ml at 0 min, NS) and glucagon-stimulated (0.23 ± 0.07 vs 0.31 ± 0.16 pg/ml at 6 min, NS) C-peptide levels, showing a virtually absent β-cell secretion in the two groups. These findings indicate that: 1) ICA in some Type I diabetic subjects may persist in the absence of a residual C-peptide secretion and therefore independently of the fate of β-cell autoantigen(s); 2) the long-term persistence of ICA identifies Type I diabetic patients as preferentially female, with an older age of onset and with other associated organ-specific autoimmunities; 3) the mechanisms of islet autoimmune response are heterogeneous.",
author = "E. Bosi and Andreotti, {A. C.} and Girardi, {A. M.} and Bottazzo, {G. F.} and G. Pozza",
year = "1991",
language = "English",
volume = "4",
pages = "319--323",
journal = "Diabetes, Nutrition and Metabolism - Clinical and Experimental",
issn = "0394-3402",
publisher = "Editrice Kurtis s.r.l.",
number = "4",

}

TY - JOUR

T1 - The long-term persistence of islet cell antibodies in Type I diabetic patients is unrelated to residual β-cell function

AU - Bosi, E.

AU - Andreotti, A. C.

AU - Girardi, A. M.

AU - Bottazzo, G. F.

AU - Pozza, G.

PY - 1991

Y1 - 1991

N2 - Islet cell antibodies (ICA) disappear in most Type I diabetic subjects within months or a few years after diagnosis, possibly reflecting the disappearance of β-cell autoantigen. In a minority of patients, ICA tend to persist indefinitely. The aim of this study was to evaluate whether the persistence of ICA reflects the persistence of functioning β-cell as a source of autoantigen immunization. In 19 longstanding Type I diabetic patients, selected for having (n = 9) detectable ICA (64.4 ± 8.01 JDF units) or not (n = 10) and matched for the duration of the disease (17.1 ± 3.6 vs 19.1 ± 1.5 yr, respectively), C-peptide secretion was evaluated by an i.v. glucagon test. The insulin requirement and metabolic control of patients with ICA were similar to those without detectable ICA. In contrast, patients with ICA were mostly females (p <0.02), older at diagnosis (p <0.02), with a higher prevalence of associated thyroid (p <0.005) and gastric (p <0.05) autoantibodies and autoimmune diseases (p <0.02). No differences were observed between patients with or without ICA in basal (0.2 ± 0.06 vs 0.10 ± 0.58 pg/ml at 0 min, NS) and glucagon-stimulated (0.23 ± 0.07 vs 0.31 ± 0.16 pg/ml at 6 min, NS) C-peptide levels, showing a virtually absent β-cell secretion in the two groups. These findings indicate that: 1) ICA in some Type I diabetic subjects may persist in the absence of a residual C-peptide secretion and therefore independently of the fate of β-cell autoantigen(s); 2) the long-term persistence of ICA identifies Type I diabetic patients as preferentially female, with an older age of onset and with other associated organ-specific autoimmunities; 3) the mechanisms of islet autoimmune response are heterogeneous.

AB - Islet cell antibodies (ICA) disappear in most Type I diabetic subjects within months or a few years after diagnosis, possibly reflecting the disappearance of β-cell autoantigen. In a minority of patients, ICA tend to persist indefinitely. The aim of this study was to evaluate whether the persistence of ICA reflects the persistence of functioning β-cell as a source of autoantigen immunization. In 19 longstanding Type I diabetic patients, selected for having (n = 9) detectable ICA (64.4 ± 8.01 JDF units) or not (n = 10) and matched for the duration of the disease (17.1 ± 3.6 vs 19.1 ± 1.5 yr, respectively), C-peptide secretion was evaluated by an i.v. glucagon test. The insulin requirement and metabolic control of patients with ICA were similar to those without detectable ICA. In contrast, patients with ICA were mostly females (p <0.02), older at diagnosis (p <0.02), with a higher prevalence of associated thyroid (p <0.005) and gastric (p <0.05) autoantibodies and autoimmune diseases (p <0.02). No differences were observed between patients with or without ICA in basal (0.2 ± 0.06 vs 0.10 ± 0.58 pg/ml at 0 min, NS) and glucagon-stimulated (0.23 ± 0.07 vs 0.31 ± 0.16 pg/ml at 6 min, NS) C-peptide levels, showing a virtually absent β-cell secretion in the two groups. These findings indicate that: 1) ICA in some Type I diabetic subjects may persist in the absence of a residual C-peptide secretion and therefore independently of the fate of β-cell autoantigen(s); 2) the long-term persistence of ICA identifies Type I diabetic patients as preferentially female, with an older age of onset and with other associated organ-specific autoimmunities; 3) the mechanisms of islet autoimmune response are heterogeneous.

UR - http://www.scopus.com/inward/record.url?scp=0026349639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026349639&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026349639

VL - 4

SP - 319

EP - 323

JO - Diabetes, Nutrition and Metabolism - Clinical and Experimental

JF - Diabetes, Nutrition and Metabolism - Clinical and Experimental

SN - 0394-3402

IS - 4

ER -